Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY)

Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy

(2016) Scott MacDiarmid et al.   JOURNAL OF UROLOGY

Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)

(2015) Paul Abrams et al.   EUROPEAN UROLOGY

The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials

(2015) D. Castro-Diaz et al.   QUALITY OF LIFE RESEARCH

Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013

(2014) Marcus J. Drake   NEUROUROLOGY AND URODYNAMICS

Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison

(2013) Khaled Maman et al.   EUROPEAN UROLOGY

A phase II dose-ranging study of mirabegron in patients with overactive bladder

(2013) Christopher R. Chapple et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

(2012) Vik Khullar et al.   EUROPEAN UROLOGY

Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder

(2012) Victor W. Nitti et al.   JOURNAL OF UROLOGY

Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature

(2011) C. C. Sexton et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Patient-reported reasons for discontinuing overactive bladder medication

(2009) Joshua S. Benner et al.   BJU INTERNATIONAL

Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo

(2009) Philip EV Van Kerrebroeck et al.   Health and Quality of Life Outcomes

Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy

(2008) N. Zinner et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE